SAN DIEGO, Sept. 17 BioMed Realty Trust, Inc.(NYSE: BMR) today announced that its board of directors has declared a thirdquarter 2007 dividend of $0.31 per share of common stock. The dividend isequivalent to an annualized dividend of $1.24 per common share.
BioMed also announced that its board of directors has declared a dividendof $0.46094 per share of the company's 7.375% Series A Cumulative RedeemablePreferred Stock for the period from July 16, 2007 through October 15, 2007.The dividends are payable on October 15, 2007 to stockholders of record at theclose of business on September 28, 2007.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focusedon Providing Real Estate to the Life Science Industry(TM). The company'stenants primarily include biotechnology and pharmaceutical companies,scientific research institutions, government agencies and other entitiesinvolved in the life science industry. BioMed Realty Trust owns or hasinterests in 69 properties, representing 105 buildings with approximately 8.8million rentable square feet, as well as approximately 1.7 million square feetof development in progress. These properties are located predominantly in themajor U.S. life science markets of Boston, San Diego, San Francisco, Seattle,Maryland, Pennsylvania and New York/New Jersey, which have well-establishedreputations as centers for scientific research. Additional information isavailable at http://www.biomedrealty.com.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 based on currentexpectations, forecasts and assumptions that involve risks and uncertaintiesthat could cause actual outcomes and results to differ materially. Theserisks and uncertainties include, without limitation: general risks affectingthe real estate industry (including, without limitation, the inability toenter into or renew leases, dependence on tenants' financial condition, andcompetition from other developers, owners and operators of real estate);adverse economic or real estate developments in the life science industry orthe company's target markets; risks associated with the availability and termsof financing and the use of debt to fund acquisitions and developments;failure to manage effectively the company's growth and expansion into newmarkets, or to complete or integrate acquisitions and developmentssuccessfully; risks and uncertainties affecting property development andconstruction; risks associated with downturns in the national and localeconomies, increases in interest rates, and volatility in the securitiesmarkets; potential liability for uninsured losses and environmentalcontamination; risks associated with the company's potential failure toqualify as a REIT under the Internal Revenue Code of 1986, as amended, andpossible adverse changes in tax and environmental laws; and risks associatedwith the company's dependence on key personnel whose continued service is notguaranteed. For a further list and description of such risks anduncertainties, see the reports filed by the company with the Securities andExchange Commission, including the company's most recent annual report on Form10-K and quarterly reports on Form 10-Q. The company disclaims any intentionor obligation to update or revise any forward-looking statements, whether as aresult of new information, future events or otherwise.
SOURCE BioMed Realty Trust, Inc.